Skip to main content

Table 3 The quality of headache according to type of vaccines used (n = 131)

From: Headache following vaccination against COVID-19 among healthcare workers with a history of COVID-19 infection: a cross-sectional study in Iran with a meta-analytic review of the literature

Characteristics

Astrazeneca

Sinopharm

Sputnik

Baharat

P value

Form of headache

    

0.984

Early

23 (85.2)

10 (83.3)

69 (82.1)

6 (85.7)

 

Delayed

4 (14.8)

2 916.7)

15 (17.9)

1 (14.3)

 

Pattern of headache

    

0.046

Pressing

20 (74.1)

8 (66.7)

63 (75.0)

4 (57.1)

 

Pulsatile

1 (3.7)

4 (33.3)

13 (15.5)

2 (28.6)

 

Neuralgic type

6 (22.2)

0 (0.0)

8 (9.5)

1 (14.3)

 

Location of headache

    

0.814

Frontal

0 (0.0)

2 (16.7)

10 (12.0)

1 (14.3)

 

Temporal

2 (7.4)

1 (8.3)

10 (12.0)

0 (0.0)

 

Occipital

0 (0.0)

0 (0.0)

4 (4.8)

0 (0.0)

 

Parietal

3 (11.1)

0 (0.0)

4 (4.8)

0 (0.0)

 

Diffuse

10 (37.0)

5 (41.7)

23 (27.7)

5 (71.4)

 

Neck

0 (0.0)

0 (0.0)

1 (1.2)

0 (0.0)

 

Mixed

12 (44.4)

4 (33.3)

31 (37.3)

1 (14.3)

Â